[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer.

scientific article published on 23 May 2018

[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1371/JOURNAL.PONE.0197754
P932PMC publication ID5965848
P698PubMed publication ID29791503

P50authorLuca PresottoQ57077231
Alessandro StefanoQ57078063
Rosa Maria MorescoQ88784635
Nadia ZaffaroniQ38591092
P2093author name stringMaria Grazia Daidone
Emilio Bombardieri
Silvia Valtorta
Isabella Raccagni
Sara Belloli
Giorgio Russo
Monica Tortoreto
Anna Bogni
Claudio Pascali
P2860cites workImaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography.Q53496753
Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer.Q54343436
Simple preparation and purification of ethanol-free solutions of 3'-deoxy-3'-[18F]fluorothymidine by means of disposable solid-phase extraction cartridgesQ82975908
Pathologic complete response after neoadjuvant therapy of breast cancer: pitfalls and shortcomingsQ83769974
Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapyQ84806666
VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cellsQ38941727
Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast CancerQ41624801
The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.Q44735837
Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancerQ46676989
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancerQ46771645
Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methodsQ46788429
Usefulness of 3'-[F-18]fluoro-3'-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy.Q46872269
An enhanced random walk algorithm for delineation of head and neck cancers in PET studies.Q48350228
Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.Q48444536
Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancerQ49017971
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.Q51009203
The Synergistic Effect of Selumetinib/Docetaxel Combination Therapy Monitored by [(18)F]FDG/[(18)F]FLT PET and Diffusion-Weighted Magnetic Resonance Imaging in a Colorectal Tumor Xenograft Model.Q52991636
¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.Q53061114
[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.Q53194822
Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aimQ53261275
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Q28131668
Early detection of response to experimental chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in human ovary cancer xenografts in miceQ28475583
[18F]FLT and [18F]FDG PET for non-invasive treatment monitoring of the nicotinamide phosphoribosyltransferase inhibitor APO866 in human xenograftsQ28484852
Triple-Negative Breast CancerQ29391607
Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.Q33750115
Triple-negative breast cancerQ34274939
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Q34476337
Histological, molecular and functional subtypes of breast cancersQ34616569
[18F]FDG and [18F]FLT positron emission tomography imaging following treatment with belinostat in human ovary cancer xenografts in miceQ34645445
Triple-negative breast cancer: new perspectives for targeted therapies.Q35001758
Imaging of treatment response to the combination of carboplatin and paclitaxel in human ovarian cancer xenograft tumors in mice using FDG and FLT PETQ35081130
18F-FDG and 18F-FLT-PET imaging for monitoring everolimus effect on tumor-growth in neuroendocrine tumors: studies in human tumor xenografts in miceQ35120054
Choosing the right cell line for breast cancer researchQ35608671
How can grafted breast cancer models be optimized?Q35760911
[18F]FLT-PET in oncology: current status and opportunitiesQ35964138
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancerQ36495792
A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688Q36533964
18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancerQ36557319
Molecular imaging as a tool for translating breast cancer scienceQ37019264
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imagingQ37522770
Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.Q37580294
Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patientsQ37705395
Molecular imaging for monitoring treatment response in breast cancer patients.Q38094852
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue5
P407language of work or nameEnglishQ1860
P304page(s)e0197754
P577publication date2018-05-23
P1433published inPLOS OneQ564954
P1476title[18F]FDG and [18F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
P478volume13

Reverse relations

cites work (P2860)
Q91974693Metabolic reprogramming in triple-negative breast cancer
Q90618474Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models